Swedish Orphan Biovitrum AB (publ) (Sobi), a Sweden-based biopharmaceutical company, has received approval for its Kineret (anakinra) from the Russian Federation's Ministry of Health, it was reported on Tuesday.
The product is intended for the treatment of Cryopyrin associated periodic syndromes (CAPS). It is an interleukin-1 receptor antagonist that is indicated in the US for the reduction in signs and symptoms and for slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) and for the treatment of neonatal-onset multisystem inflammatory disease (NOMID), a form of CAPS. CAPS are a group of rare genetic autoinflammatory diseases causing a number of inflammatory responses such as fever, pain sensitization, bone and cartilage destruction and acute plasma protein responses.
Norbert Oppitz, head of Immunology and International at Sobi, stated: "We are excited to announce the approval of this important treatment and we look forward to serving patients with Cryopyrin associated periodic syndromes in Russia. Today's announcement also marks a significant milestone for Sobi's future ambition, as Russia is a key market for our geographic expansion strategy over the next five years."
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007